Alex Herrera, MD
Hematology · Duarte, CANPI 1275761553
Payments from drug & device makers
Across 609 payments — averaging $83,624 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$16.2M
- E.r. Squibb & Sons, L.L.C.$12.9M
- Merck$11.9M
- Pfizer$6.4M
- Genentech, Inc.$2.5M
- Gilead$237K
- plus $769K from 24 others
Across 30 payments — averaging $587.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$17K
- Pfizer$330
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 201 | $16,158,084 |
| E.r. Squibb & Sons, L.L.C. | 29 | $12,899,390 |
| Merck | 143 | $11,934,236 |
| Pfizer | 35 | $6,379,646 |
| Genentech, Inc. | 70 | $2,549,647 |
| Gilead(2 entities) | 25 | $236,770 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $216,220 |
| AbbVie | 11 | $212,007 |
| ADC Therapeutics America, Inc. | 8 | $143,712 |
| Astrazeneca UK Limited | 8 | $128,151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $13,699 |
| F. Hoffmann-la Roche AG | 18 | $13,606 |
| AstraZeneca | 13 | $10,909 |
| Roche Sequencing Solutions, Inc. | 1 | $5,000 |
| Karyopharm Therapeutics Inc. | 3 | $3,513 |
| Daiichi Sankyo Inc. | 1 | $3,383 |
| Eli Lilly | 4 | $3,295 |
| Bristol Myers Squibb | 7 | $3,260 |
| Genentech USA, Inc. | 7 | $3,028 |
| Regeneron | 1 | $2,620 |
| Genmab U.S., Inc. | 3 | $2,385 |
| Incyte Corporation | 3 | $2,225 |
| Sanofi US Services Inc. | 1 | $1,490 |
| Beigene USA, Inc. | 2 | $175 |
| Morphosys, US Inc. | 1 | $138 |
| Novartis | 1 | $95 |
| Lilly USA, LLC | 3 | $45 |
| Amgen | 2 | $35 |
| Beone Medicines USA, Inc. | 1 | $27 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$50,926,803 in reported general payments places this provider in the 95th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Tycel PhillipsDuarte$21.6M
- Lihua BuddeDuarte$21.5M
- Tanya SiddiqiDuarte$18.8M
- Amrita KrishnanDuarte$14M
- Anthony SteinDuarte$12.1M
- Alexey DanilovDuarte$11.3M
- Vincent ChungDuarte$11.1M
- Vinod PullarkatDuarte$10M
- Ibrahim AldossDuarte$9.9M
- Haris AliDuarte$7.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.